VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q56440814  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000306.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q56440814‏
024 ‎‡a  0000-0001-7313-4446‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q56440814‏
100 0 ‎‡a  Janet A Dunn‏ ‎‡c  researcher‏ ‎‡9  en-gb‏
375 ‎‡a  2‏ ‎‡2  iso5218‏
400 0 ‎‡a  Janet A Dunn‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Janet A Dunn‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's 195 Patient's experiences of a pre and post surgery rehabilitation programme for lung cancer‏
670 ‎‡a  Author's 195 Patient's experiences of a pre and post surgery rehabilitation programme for lung cancer (Rehabilitation Of lung Cancer (ROC) programme): a qualitative interview study‏
670 ‎‡a  Author's A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease‏
670 ‎‡a  Author's A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines‏
670 ‎‡a  Author's A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities‏
670 ‎‡a  Author's A network analysis to identify mediators of germline-driven differences in breast cancer prognosis‏
670 ‎‡a  Author's A 'new normal': Exploring the disruption of a poor prognostic cancer diagnosis using interviews and participant-produced photographs.‏
670 ‎‡a  Author's A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer‏
670 ‎‡a  Author's A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer‏
670 ‎‡a  Author's A qualitative systematic review exploring lay understanding of cancer by adults without a cancer diagnosis‏
670 ‎‡a  Author's A Randomised Controlled Trial to Evaluate both the Role and the Optimal Fractionation of Radiotherapy in the Conservative Management of Early Breast Cancer‏
670 ‎‡a  Author's A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix‏
670 ‎‡a  Author's A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer‏
670 ‎‡a  Author's A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma‏
670 ‎‡a  Author's A review of the issues and challenges involved in using participant-produced photographs in nursing research.‏
670 ‎‡a  Author's Abstract P3-08-09: Is it me or is it hot in here? Hot flushes‏
670 ‎‡a  Author's Abstract P3-08-09: Is it me or is it hot in here? Hot flushes (or flashes): An unmet need. UK NCRI breast clinical studies group working party on symptom management (vasomotor)‏
670 ‎‡a  Author's Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer‏
670 ‎‡a  Author's Abstract PD2-02: NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer‏
670 ‎‡a  Author's Common germline polymorphisms associated with breast cancer-specific survival‏
670 ‎‡a  Author's Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone‏
670 ‎‡a  Author's Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3‏
670 ‎‡a  Author's Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial‏
670 ‎‡a  Author's Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.‏
670 ‎‡a  Author's Etoposide protein binding in cancer patients‏
670 ‎‡a  Author's Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population.‏
670 ‎‡a  Author's Feasibility of recruitment to an oral dysplasia trial in the United Kingdom‏
670 ‎‡a  Author's Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy‏
670 ‎‡a  Author's Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group‏
670 ‎‡a  Author's FKBPL: a marker of good prognosis in breast cancer‏
670 ‎‡a  Author's Follow-up in early breast cancer--a surgical and radiological perceptive.‏
670 ‎‡a  Author's Genome-wide association study of germline variants and breast cancer-specific mortality‏
670 ‎‡a  Author's Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials‏
670 ‎‡a  Author's Identification of novel genetic markers of breast cancer survival‏
670 ‎‡a  Author's Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse‏
670 ‎‡a  Author's Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.‏
670 ‎‡a  Author's Lesion size and histology of atypical cervical transformation zone‏
670 ‎‡a  Author's LIHNCS - Lugol's iodine in head and neck cancer surgery: a multicentre, randomised controlled trial assessing the effectiveness of Lugol's iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection m‏
670 ‎‡a  Author's Long–Term Risk of Salvage Cystectomy after Radiotherapy for Muscle–Invasive Bladder Cancer‏
670 ‎‡a  Author's Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial‏
670 ‎‡a  Author's Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platform‏
670 ‎‡a  Author's Management of advanced nodal disease in patients treated with primary chemoradiotherapy‏
670 ‎‡a  Author's Management of hot flushes in UK breast cancer patients: clinician and patient perspectives.‏
670 ‎‡a  Author's MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma‏
670 ‎‡a  Author's Multi-omic machine learning predictor of breast cancer therapy response‏
670 ‎‡a  Author's National randomised controlled trial is needed‏
670 ‎‡a  Author's Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder‏
670 ‎‡a  Author's Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?‏
670 ‎‡a  Author's Nursing student attitudes to psychiatric nursing and psychiatric disorders in New Zealand‏
670 ‎‡a  Author's Observer variability among colposcopists from the West Midlands region‏
670 ‎‡a  Author's OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism‏
670 ‎‡a  Author's OP077‏
670 ‎‡a  Author's OP080‏
670 ‎‡a  Author's OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer‏
670 ‎‡a  Author's Options for early breast cancer follow-up in primary and secondary care - a systematic review‏
670 ‎‡a  Author's OT1-02-08: The PERSEPHONE Trial: Duration of Trastuzumab with Chemotherapy in Women with HER2 Positive Early Breast Cancer. Changing the Randomisation Point To Address Potential Barriers to Recruitment‏
670 ‎‡a  Author's Pathogenesis of gall stones in Crohn's disease: an alternative explanation‏
670 ‎‡a  Author's PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes‏
670 ‎‡a  Author's PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer‏
670 ‎‡a  Author's PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metasta‏
670 ‎‡a  Author's Phase III Randomised Study of Zoladex versus Stilboestrol in the Treatment of Advanced Prostate Cancer‏
670 ‎‡a  Author's Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer‏
670 ‎‡a  Author's Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial‏
670 ‎‡a  Author's Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests.‏
670 ‎‡a  Author's Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also‏
670 ‎‡a  Author's Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).‏
670 ‎‡a  Author's Pregnancy outcome after large loop excision of the cervical transformation zone‏
670 ‎‡a  Author's Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry‏
670 ‎‡a  Author's Prognosis by breast cancer subtypes in patients treated with adjuvant chemotherapy in a clinical trial‏
670 ‎‡a  Author's Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial‏
670 ‎‡a  Author's Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT‏
670 ‎‡a  Author's Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group.‏
670 ‎‡a  Author's Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery‏
670 ‎‡a  Author's Radiation Therapy Variation in the Randomized Phase 3 Positron Emission Tomography Neck Study‏
670 ‎‡a  Author's Radical treatment of muscle-invasive bladder cancer—are options equal?‏
670 ‎‡a  Author's Rapid diagnostic service for patients with haematuria.‏
670 ‎‡a  Author's Repeat testing for haematuria and underlying urological pathology‏
670 ‎‡a  Author's Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel‏
670 ‎‡a  Author's Resection-line involvement in gastric cancer: A continuing problem‏
670 ‎‡a  Author's Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer‏
670 ‎‡a  Author's Screening for gastric cancer by Helicobacter pylori serology: a retrospective study.‏
670 ‎‡a  Author's Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.‏
670 ‎‡a  Author's Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC‏
670 ‎‡a  Author's Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V Trial‏
670 ‎‡a  Author's Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT‏
670 ‎‡a  Author's Socio-economic deprivation and survival in bladder cancer‏
670 ‎‡a  Author's Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival‏
670 ‎‡a  Author's Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer‏
670 ‎‡a  Author's Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study‏
670 ‎‡a  Author's The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma‏
670 ‎‡a  Author's The quality of life of early breast cancer patients treated by two different radiotherapy regimens.‏
670 ‎‡a  Author's The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study‏
670 ‎‡a  Author's The role of PET CT in the management of advanced nodal head neck cancer post chemoradiotherapy‏
670 ‎‡a  Author's The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up‏
670 ‎‡a  Author's The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group‏
670 ‎‡a  Author's The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study.‏
670 ‎‡a  Author's The value of source data verification in a cancer clinical trial‏
670 ‎‡a  Author's Thoracoscore fails to predict complications following elective lung resection‏
670 ‎‡a  Author's Trastuzumab-associated cardiac events in the Persephone trial‏
670 ‎‡a  Author's Treatment Preferences of Urologists in Great Britain and Ireland in the Management of Prostate Cancer‏
670 ‎‡a  Author's UK ethnicity data collection for healthcare statistics: the South Asian perspective‏
670 ‎‡a  Author's Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.‏
670 ‎‡a  Author's Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.‏
670 ‎‡a  Author's Video colpography: a new technique for secondary cervical screening‏
909 ‎‡a  (orcid) 0000000173134446‏ ‎‡9  1‏
912 ‎‡a  networkanalysistoidentifymediatorsofgermlinedrivendifferencesinbreastcancerprognosis‏ ‎‡A  A network analysis to identify mediators of germline-driven differences in breast cancer prognosis‏ ‎‡9  1‏
912 ‎‡a  genomicapproachtotherapeutictargetvalidationidentifiesaglucoseloweringglp1rvariantprotectiveforcoronaryheartdisease‏ ‎‡A  A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease‏ ‎‡9  1‏
912 ‎‡a  genomewideassociationstudyofgermlinevariantsandbreastcancerspecificmortality‏ ‎‡A  Genome-wide association study of germline variants and breast cancer-specific mortality‏ ‎‡9  1‏
912 ‎‡a  identificationofnovelgeneticmarkersofbreastcancersurvival‏ ‎‡A  Identification of novel genetic markers of breast cancer survival‏ ‎‡9  1‏
912 ‎‡a  commongermlinepolymorphismsassociatedwithbreastcancerspecificsurvival‏ ‎‡A  Common germline polymorphisms associated with breast cancer-specific survival‏ ‎‡9  1‏
919 ‎‡a  predictinganthracyclinebenefittop2aandcep17notonlybutalso‏ ‎‡A  Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also‏ ‎‡9  1‏
919 ‎‡a  practicalitiesofusinganadaptivedesignfordecisionmakingwithintheoptimatrialoptimalpersonalizedtreatmentofearlybreastcancerusingmultiparametertests‏ ‎‡A  Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests.‏ ‎‡9  1‏
919 ‎‡a  phase3randomizedtrialassessingrofecoxibintheadjuvantsettingofcolorectalcancerfinalresultsofthevictortrial‏ ‎‡A  Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial‏ ‎‡9  1‏
919 ‎‡a  phase3randomizedcomparisonofgemcitabineversusgemcitabinepluscapecitabineinpatientswithadvancedpancreaticcancer‏ ‎‡A  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer‏ ‎‡9  1‏
919 ‎‡a  phase3randomisedstudyofzoladexversusstilboestrolinthetreatmentofadvancedprostatecancer‏ ‎‡A  Phase III Randomised Study of Zoladex versus Stilboestrol in the Treatment of Advanced Prostate Cancer‏ ‎‡9  1‏
919 ‎‡a  treatmentpreferencesofurologistsingreatbritainandirelandinthemanagementofprostatecancer‏ ‎‡A  Treatment Preferences of Urologists in Great Britain and Ireland in the Management of Prostate Cancer‏ ‎‡9  1‏
919 ‎‡a  managementofhotflushesinukbreastcancerpatientsclinicianandpatientperspectives‏ ‎‡A  Management of hot flushes in UK breast cancer patients: clinician and patient perspectives.‏ ‎‡9  1‏
919 ‎‡a  stratifyingriskofinfectionandresponsetotherapyinpatientswithmyelomaaprognosticstudy‏ ‎‡A  Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study‏ ‎‡9  1‏
919 ‎‡a  petneckamulticentrerandomisedphase3noninferioritytrialcomparingapositronemissiontomographycomputerisedtomographyguidedwatchandwaitpolicywithplannedneckdissectioninthemanagementoflocallyadvancedn2n3nodalmetasta‏ ‎‡A  PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metasta‏ ‎‡9  1‏
919 ‎‡a  petctsurveillanceversusneckdissectioninadvancedheadandneckcancer‏ ‎‡A  PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer‏ ‎‡9  1‏
919 ‎‡a  pdl1proteinexpressioninbreastcancerisrareenrichedinbasalliketumoursandassociatedwithinfiltratinglymphocytes‏ ‎‡A  PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes‏ ‎‡9  1‏
919 ‎‡a  useofearlydecisionmodellingandvalueofinformationanalysisinanadaptivetrialdesignresultsfromtheoptimapreliminarystudy‏ ‎‡A  The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study.‏ ‎‡9  1‏
919 ‎‡a  oc11anticoagulationtherapyinselectedcancerpatientsatriskofrecurrenceofvenousthromboembolism‏ ‎‡A  OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism‏ ‎‡9  1‏
919 ‎‡a  effectsoftheadditionofgemcitabineandpaclitaxel1sequencinginneoadjuvantsequentialepirubicincyclophosphamideandpaclitaxelforwomenwithhighriskearlybreastcancerneotangoanopenlabel22factorialrandomisedphase3‏ ‎‡A  Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3‏ ‎‡9  1‏
919 ‎‡a  efficacyofneoadjuvantbevacizumabaddedtodocetaxelfollowedbyfluorouracilepirubicinandcyclophosphamideforwomenwithher2negativeearlybreastcancerartemisanopenlabelrandomisedphase3trial‏ ‎‡A  Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial‏ ‎‡9  1‏
919 ‎‡a  epirubicinandcyclophosphamidemethotrexateandfluorouracilasadjuvanttherapyforearlybreastcancer‏ ‎‡A  Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.‏ ‎‡9  1‏
919 ‎‡a  etoposideproteinbindingincancerpatients‏ ‎‡A  Etoposide protein binding in cancer patients‏ ‎‡9  1‏
919 ‎‡a  evaluationoftheaccuracyofserummmp9asatestforcolorectalcancerinaprimarycarepopulation‏ ‎‡A  Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population.‏ ‎‡9  1‏
919 ‎‡a  feasibilityofrecruitmenttoanoraldysplasiatrialintheunitedkingdom‏ ‎‡A  Feasibility of recruitment to an oral dysplasia trial in the United Kingdom‏ ‎‡9  1‏
919 ‎‡a  5yearfollowupofaprospectiverandomisedmulticentretrialofweeklychemotherapy‏ ‎‡A  Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy‏ ‎‡9  1‏
919 ‎‡a  5yearfollowupofaprospectiverandomisedmulticentretrialofweeklychemotherapycapometversuscyclicalchemotherapychopmtxinthetreatmentofaggressivenonhodgkinslymphomacentrallymphomagroup‏ ‎‡A  Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group‏ ‎‡9  1‏
919 ‎‡a  observervariabilityamongcolposcopistsfromthewestmidlandsregion‏ ‎‡A  Observer variability among colposcopists from the West Midlands region‏ ‎‡9  1‏
919 ‎‡a  nursingstudentattitudestopsychiatricnursingandpsychiatricdisordersinnewzealand‏ ‎‡A  Nursing student attitudes to psychiatric nursing and psychiatric disorders in New Zealand‏ ‎‡9  1‏
919 ‎‡a  pathogenesisofgallstonesincrohnsdiseaseanalternativeexplanation‏ ‎‡A  Pathogenesis of gall stones in Crohn's disease: an alternative explanation‏ ‎‡9  1‏
919 ‎‡a  steroidreceptorsps2andcathepsin500inearlyclinicallynodenegativebreastcancer‏ ‎‡A  Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer‏ ‎‡9  1‏
919 ‎‡a  serumthymidinekinaseasaprognosticindicatorforpatientswithmultiplemyelomaresultsfromthemrcuk5trial‏ ‎‡A  Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V Trial‏ ‎‡9  1‏
919 ‎‡a  ot10208thepersephonetrialdurationoftrastuzumabwithchemotherapyinwomenwithher2positiveearlybreastcancerchangingtherandomisationpointtoaddresspotentialbarrierstorecruitment‏ ‎‡A  OT1-02-08: The PERSEPHONE Trial: Duration of Trastuzumab with Chemotherapy in Women with HER2 Positive Early Breast Cancer. Changing the Randomisation Point To Address Potential Barriers to Recruitment‏ ‎‡9  1‏
919 ‎‡a  serumthymidinekinaseasaprognosticindicatorforpatientswithmultiplemyelomaresultsfromthemrc‏ ‎‡A  Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC‏ ‎‡9  1‏
919 ‎‡a  selectingbreastcancerpatientsforchemotherapytheopeningoftheukoptimatrial‏ ‎‡A  Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.‏ ‎‡9  1‏
919 ‎‡a  optionsforearlybreastcancerfollowupinprimaryandsecondarycareasystematicreview‏ ‎‡A  Options for early breast cancer follow-up in primary and secondary care - a systematic review‏ ‎‡9  1‏
919 ‎‡a  screeningforgastriccancerbyhelicobacterpyloriserologyaretrospectivestudy‏ ‎‡A  Screening for gastric cancer by Helicobacter pylori serology: a retrospective study.‏ ‎‡9  1‏
919 ‎‡a  rofecoxibandcardiovascularadverseeventsinadjuvanttreatmentofcolorectalcancer‏ ‎‡A  Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer‏ ‎‡9  1‏
919 ‎‡a  optimaprelimarandomisedfeasibilitystudyofpersonalisedcareinthetreatmentofwomenwithearlybreastcancer‏ ‎‡A  OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer‏ ‎‡9  1‏
919 ‎‡a  resectionlineinvolvementingastriccanceracontinuingproblem‏ ‎‡A  Resection-line involvement in gastric cancer: A continuing problem‏ ‎‡9  1‏
919 ‎‡a  replicationofgeneticpolymorphismsreportedtobeassociatedwithtaxanerelatedsensoryneuropathyinpatientswithearlybreastcancertreatedwithpaclitaxel‏ ‎‡A  Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel‏ ‎‡9  1‏
919 ‎‡a  op080‏ ‎‡A  OP080‏ ‎‡9  1‏
919 ‎‡a  updated2016eauguidelinesonmuscleinvasiveandmetastaticbladdercancer‏ ‎‡A  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.‏ ‎‡9  1‏
919 ‎‡a  solublesyndecan1levelatdiagnosisisanindependentprognosticfactorinmultiplemyelomaandtheextentoffallfromdiagnosistoplateaupredictsforoverallsurvival‏ ‎‡A  Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival‏ ‎‡9  1‏
919 ‎‡a  op077‏ ‎‡A  OP077‏ ‎‡9  1‏
919 ‎‡a  selectionofcasesforrandomisedtrialsaregistrysurveyofconcurrenttrialandnontrialpatientsthebritishstomachcancergroup‏ ‎‡A  The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group‏ ‎‡9  1‏
919 ‎‡a  socioeconomicdeprivationandsurvivalinbladdercancer‏ ‎‡A  Socio-economic deprivation and survival in bladder cancer‏ ‎‡9  1‏
919 ‎‡a  videocolpographyanewtechniqueforsecondarycervicalscreening‏ ‎‡A  Video colpography: a new technique for secondary cervical screening‏ ‎‡9  1‏
919 ‎‡a  fkbplamarkerofgoodprognosisinbreastcancer‏ ‎‡A  FKBPL: a marker of good prognosis in breast cancer‏ ‎‡9  1‏
919 ‎‡a  nestedcohortstudyof6248earlybreastcancerpatientstreatedinneoadjuvantandadjuvantchemotherapytrialsinvestigatingtheprognosticvalueofchemotherapyrelatedtoxicities‏ ‎‡A  A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities‏ ‎‡9  1‏
919 ‎‡a  trastuzumabassociatedcardiaceventsinthepersephonetrial‏ ‎‡A  Trastuzumab-associated cardiac events in the Persephone trial‏ ‎‡9  1‏
919 ‎‡a  6versus12monthsadjuvanttrastuzumabinpatientswithher2positiveearlybreastcancerthepersephonenoninferiorityrct‏ ‎‡A  Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT‏ ‎‡9  1‏
919 ‎‡a  neoadjuvanttrialsinearlybreastcancerpathologicalresponseatsurgeryandcorrelationtolongertermoutcomeswhatdoesitallmean‏ ‎‡A  Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?‏ ‎‡9  1‏
919 ‎‡a  2britishstomachcancergrouptrialofadjuvantradiotherapyorchemotherapyinresectablegastriccancer5yearfollowup‏ ‎‡A  The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up‏ ‎‡9  1‏
919 ‎‡a  repeattestingforhaematuriaandunderlyingurologicalpathology‏ ‎‡A  Repeat testing for haematuria and underlying urological pathology‏ ‎‡9  1‏
919 ‎‡a  literaturereviewofappliedadaptivedesignmethodologywithinthefieldofoncologyinrandomisedcontrolledtrialsandaproposedextensiontotheconsortguidelines‏ ‎‡A  A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines‏ ‎‡9  1‏
919 ‎‡a  195patientsexperiencesofapreandpostsurgeryrehabilitationprogrammeforlungcancerrehabilitationoflungcancerrocprogrammeaqualitativeinterviewstudy‏ ‎‡A  195 Patient's experiences of a pre and post surgery rehabilitation programme for lung cancer (Rehabilitation Of lung Cancer (ROC) programme): a qualitative interview study‏ ‎‡9  1‏
919 ‎‡a  195patientsexperiencesofapreandpostsurgeryrehabilitationprogrammeforlungcancer‏ ‎‡A  195 Patient's experiences of a pre and post surgery rehabilitation programme for lung cancer‏ ‎‡9  1‏
919 ‎‡a  abstractp30809isitmeorisithotinherehotflushesorflashesanunmetneedukncribreastclinicalstudiesgroupworkingpartyonsymptommanagementvasomotor‏ ‎‡A  Abstract P3-08-09: Is it me or is it hot in here? Hot flushes (or flashes): An unmet need. UK NCRI breast clinical studies group working party on symptom management (vasomotor)‏ ‎‡9  1‏
919 ‎‡a  abstractp60811ukoptimaprelimstudydemonstrateseconomicvalueinmoreclinicalevaluationofmultiparameterprognostictestsinearlybreastcancer‏ ‎‡A  Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer‏ ‎‡9  1‏
919 ‎‡a  abstractpd202neoexcelphase3neoadjuvanttrialofpreoperativeexemestaneorletrozole+celecoxibinthetreatmentoferpositivepostmenopausalearlybreastcancer‏ ‎‡A  Abstract PD2-02: NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer‏ ‎‡9  1‏
919 ‎‡a  newnormalexploringthedisruptionofapoorprognosticcancerdiagnosisusinginterviewsandparticipantproducedphotographs‏ ‎‡A  A 'new normal': Exploring the disruption of a poor prognostic cancer diagnosis using interviews and participant-produced photographs.‏ ‎‡9  1‏
919 ‎‡a  geographicvariationinhumanpapillomavirusrelatedoropharyngealcancerdatafrom4multinationalrandomizedtrials‏ ‎‡A  Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials‏ ‎‡9  1‏
919 ‎‡a  followupinearlybreastcancerasurgicalandradiologicalperceptive‏ ‎‡A  Follow-up in early breast cancer--a surgical and radiological perceptive.‏ ‎‡9  1‏
919 ‎‡a  influenceofsurgicalresectionandpostoperativecomplicationsonsurvivalfollowingadjuvanttreatmentforpancreaticcancerintheespac1randomizedcontrolledtrial‏ ‎‡A  Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.‏ ‎‡9  1‏
919 ‎‡a  prospectiverandomizedtrialtoevaluatedifferentoraldoseregimensofmedroxyprogesteroneacetateinwomenwithadvancedbreastcancer‏ ‎‡A  A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer‏ ‎‡9  1‏
919 ‎‡a  impactofadjuvantchemotherapyinbreastcanceronresponsetotamoxifenatrelapse‏ ‎‡A  Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse‏ ‎‡9  1‏
919 ‎‡a  prospectivestudytoassessthevalueofmmp9inimprovingtheappropriatenessofurgentreferralsforcolorectalcancer‏ ‎‡A  A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer‏ ‎‡9  1‏
919 ‎‡a  qualitativesystematicreviewexploringlayunderstandingofcancerbyadultswithoutacancerdiagnosis‏ ‎‡A  A qualitative systematic review exploring lay understanding of cancer by adults without a cancer diagnosis‏ ‎‡9  1‏
919 ‎‡a  randomisedcontrolledtrialtoevaluateboththeroleandtheoptimalfractionationofradiotherapyintheconservativemanagementofearlybreastcancer‏ ‎‡A  A Randomised Controlled Trial to Evaluate both the Role and the Optimal Fractionation of Radiotherapy in the Conservative Management of Early Breast Cancer‏ ‎‡9  1‏
919 ‎‡a  lesionsizeandhistologyofatypicalcervicaltransformationzone‏ ‎‡A  Lesion size and histology of atypical cervical transformation zone‏ ‎‡9  1‏
919 ‎‡a  randomisedprospectivephase3clinicaltrialofprimarybleomycinifosfamideandcisplatinbipchemotherapyfollowedbyradiotherapyversusradiotherapyaloneininoperablecancerofthecervix‏ ‎‡A  A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix‏ ‎‡9  1‏
919 ‎‡a  randomizedtrialofchemoradiotherapyandchemotherapyafterresectionofpancreaticcancer‏ ‎‡A  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer‏ ‎‡9  1‏
919 ‎‡a  randomizedtrialoftheeffectofclodronateonskeletalmorbidityinmultiplemyeloma‏ ‎‡A  A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma‏ ‎‡9  1‏
919 ‎‡a  reviewoftheissuesandchallengesinvolvedinusingparticipantproducedphotographsinnursingresearch‏ ‎‡A  A review of the issues and challenges involved in using participant-produced photographs in nursing research.‏ ‎‡9  1‏
919 ‎‡a  abstractp30809isitmeorisithotinherehotflushes‏ ‎‡A  Abstract P3-08-09: Is it me or is it hot in here? Hot flushes‏ ‎‡9  1‏
919 ‎‡a  comparisonofwholebodymrictandbonescintigraphyforresponseevaluationofcancertherapeuticsinmetastaticbreastcancertobone‏ ‎‡A  Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone‏ ‎‡9  1‏
919 ‎‡a  lihncslugolsiodineinheadandneckcancersurgeryamulticentrerandomisedcontrolledtrialassessingtheeffectivenessoflugolsiodinetoassistexcisionofmoderatedysplasiaseveredysplasiaandcarcinomainsituatmucosalresection1000‏ ‎‡A  LIHNCS - Lugol's iodine in head and neck cancer surgery: a multicentre, randomised controlled trial assessing the effectiveness of Lugol's iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection m‏ ‎‡9  1‏
919 ‎‡a  longtermriskofsalvagecystectomyafterradiotherapyformuscleinvasivebladdercancer‏ ‎‡A  Long–Term Risk of Salvage Cystectomy after Radiotherapy for Muscle–Invasive Bladder Cancer‏ ‎‡9  1‏
919 ‎‡a  lymphocytedensitydeterminedbycomputationalpathologyvalidatedasapredictorofresponsetoneoadjuvantchemotherapyinbreastcancersecondaryanalysisoftheartemistrial‏ ‎‡A  Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial‏ ‎‡9  1‏
919 ‎‡a  makingrandomisedtrialsmoreefficientreportofthe1meetingtodiscussthetrialforgeplatform‏ ‎‡A  Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platform‏ ‎‡9  1‏
919 ‎‡a  managementofadvancednodaldiseaseinpatientstreatedwithprimarychemoradiotherapy‏ ‎‡A  Management of advanced nodal disease in patients treated with primary chemoradiotherapy‏ ‎‡9  1‏
919 ‎‡a  rapiddiagnosticserviceforpatientswithhaematuria‏ ‎‡A  Rapid diagnostic service for patients with haematuria.‏ ‎‡9  1‏
919 ‎‡a  radicaltreatmentofmuscleinvasivebladdercancerareoptionsequal‏ ‎‡A  Radical treatment of muscle-invasive bladder cancer—are options equal?‏ ‎‡9  1‏
919 ‎‡a  radiationtherapyvariationintherandomizedphase3positronemissiontomographyneckstudy‏ ‎‡A  Radiation Therapy Variation in the Randomized Phase 3 Positron Emission Tomography Neck Study‏ ‎‡9  1‏
919 ‎‡a  roleofpetctinthemanagementofadvancednodalheadneckcancerpostchemoradiotherapy‏ ‎‡A  The role of PET CT in the management of advanced nodal head neck cancer post chemoradiotherapy‏ ‎‡9  1‏
919 ‎‡a  neoadjuvantpreemptivecisplatintherapyininvasivetransitionalcellcarcinomaofthebladder‏ ‎‡A  Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder‏ ‎‡9  1‏
919 ‎‡a  pulmonaryrehabilitationprogrammeforpatientsundergoingcurativelungcancersurgery‏ ‎‡A  Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery‏ ‎‡9  1‏
919 ‎‡a  relationshipbetweencommongeneticmarkersofbreastcancerriskandchemotherapyinducedtoxicityacasecontrolstudy‏ ‎‡A  The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study‏ ‎‡9  1‏
919 ‎‡a  qualityoflifeofearlybreastcancerpatientstreatedby2differentradiotherapyregimens‏ ‎‡A  The quality of life of early breast cancer patients treated by two different radiotherapy regimens.‏ ‎‡9  1‏
919 ‎‡a  prospectivedoubleblindplacebocontrolledrandomizedtrialofcimetidineingastriccancerbritishstomachcancergroup‏ ‎‡A  Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group.‏ ‎‡9  1‏
919 ‎‡a  nationalrandomisedcontrolledtrialisneeded‏ ‎‡A  National randomised controlled trial is needed‏ ‎‡9  1‏
919 ‎‡a  ukethnicitydatacollectionforhealthcarestatisticsthesouthasianperspective‏ ‎‡A  UK ethnicity data collection for healthcare statistics: the South Asian perspective‏ ‎‡9  1‏
919 ‎‡a  prophylacticlevofloxacintopreventinfectionsinnewlydiagnosedsymptomaticmyelomatheteammrct‏ ‎‡A  Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT‏ ‎‡9  1‏
919 ‎‡a  thoracoscorefailstopredictcomplicationsfollowingelectivelungresection‏ ‎‡A  Thoracoscore fails to predict complications following elective lung resection‏ ‎‡9  1‏
919 ‎‡a  multiomicmachinelearningpredictorofbreastcancertherapyresponse‏ ‎‡A  Multi-omic machine learning predictor of breast cancer therapy response‏ ‎‡9  1‏
919 ‎‡a  prognosisofearlybreastcancerbyimmunohistochemistrydefinedintrinsicsubtypesinpatientstreatedwithadjuvantchemotherapyintheneatbr9601trial‏ ‎‡A  Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial‏ ‎‡9  1‏
919 ‎‡a  valueofinformationanalysisofmultiparametertestsforchemotherapyinearlybreastcancertheoptimaprelimtrial‏ ‎‡A  Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.‏ ‎‡9  1‏
919 ‎‡a  valueofsourcedataverificationinacancerclinicaltrial‏ ‎‡A  The value of source data verification in a cancer clinical trial‏ ‎‡9  1‏
919 ‎‡a  prognosisbybreastcancersubtypesinpatientstreatedwithadjuvantchemotherapyinaclinicaltrial‏ ‎‡A  Prognosis by breast cancer subtypes in patients treated with adjuvant chemotherapy in a clinical trial‏ ‎‡9  1‏
919 ‎‡a  mrctrialofalpha2binterferonmaintenancetherapyin1plateauphaseofmultiplemyeloma‏ ‎‡A  MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma‏ ‎‡9  1‏
919 ‎‡a  prognosticsignificanceofintraperitonealgrowthcharacteristicsinepithelialovariancarcinoma‏ ‎‡A  The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma‏ ‎‡9  1‏
919 ‎‡a  prevalenceandtreatmentofhypovitaminosis500inthehaemodialysispopulationofcoventry‏ ‎‡A  Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry‏ ‎‡9  1‏
919 ‎‡a  pregnancyoutcomeafterlargeloopexcisionofthecervicaltransformationzone‏ ‎‡A  Pregnancy outcome after large loop excision of the cervical transformation zone‏ ‎‡9  1‏
919 ‎‡a  predictivemarkersofanthracyclinebenefitaprospectivelyplannedanalysisoftheuknationalepirubicinadjuvanttrialneatb‏ ‎‡A  Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).‏ ‎‡9  1‏
946 ‎‡a  a‏ ‎‡9  1‏
996 ‎‡2  CAOONL|ncf10520289‏
996 ‎‡2  CAOONL|ncf11207926‏
996 ‎‡2  BNF|12392839‏
996 ‎‡2  BNF|15801118‏
996 ‎‡2  NII|DA0906491X‏
996 ‎‡2  BIBSYS|12069410‏
996 ‎‡2  ISNI|0000000082770148‏
996 ‎‡2  LC|nb2008022942‏
996 ‎‡2  BIBSYS|90701098‏
996 ‎‡2  NTA|112351387‏
996 ‎‡2  LC|no 96055003‏
996 ‎‡2  SUDOC|244876908‏
996 ‎‡2  LC|n 80048515‏
996 ‎‡2  ISNI|0000000033323966‏
996 ‎‡2  CAOONL|ncf10460838‏
996 ‎‡2  ISNI|0000000108795512‏
996 ‎‡2  SUDOC|033018928‏
996 ‎‡2  NSK|000119398‏
996 ‎‡2  NTA|074782304‏
996 ‎‡2  LC|no2013069215‏
996 ‎‡2  BIBSYS|90681046‏
996 ‎‡2  NTA|130825808‏
996 ‎‡2  ISNI|0000000033894259‏
996 ‎‡2  DNB|1035331683‏
996 ‎‡2  BNF|12186292‏
996 ‎‡2  CAOONL|ncf10207591‏
996 ‎‡2  LC|n 98106998‏
996 ‎‡2  LC|n 84088325‏
996 ‎‡2  LC|no 00048405‏
996 ‎‡2  BLBNB|000359567‏
996 ‎‡2  RERO|A025239950‏
996 ‎‡2  NUKAT|n 2004095674‏
996 ‎‡2  RERO|A003198083‏
996 ‎‡2  J9U|987007280425705171‏
996 ‎‡2  J9U|987007379167405171‏
996 ‎‡2  LC|n 78000304‏
996 ‎‡2  ISNI|0000000026968037‏
996 ‎‡2  SUDOC|274442345‏
996 ‎‡2  LC|no2010029708‏
996 ‎‡2  NUKAT|n 98098125‏
996 ‎‡2  NII|DA09219754‏
996 ‎‡2  J9U|987007337614205171‏
996 ‎‡2  DNB|126345198‏
996 ‎‡2  LIH|LNB:,DY;=BE‏
996 ‎‡2  RERO|A003198087‏
996 ‎‡2  PTBNP|1270833‏
996 ‎‡2  ISNI|0000000068185743‏
996 ‎‡2  ISNI|0000000410286102‏
996 ‎‡2  NUKAT|n 2008078788‏
996 ‎‡2  CAOONL|ncf10151945‏
996 ‎‡2  SUDOC|268786275‏
996 ‎‡2  SUDOC|199381445‏
996 ‎‡2  J9U|987007422656105171‏
996 ‎‡2  NII|DA0590664X‏
996 ‎‡2  NTA|158170830‏
996 ‎‡2  LC|no2017152075‏
996 ‎‡2  PLWABN|9810538424405606‏
996 ‎‡2  LC|n 97843535‏
996 ‎‡2  SUDOC|030451337‏
996 ‎‡2  LC|n 2002100218‏
996 ‎‡2  NLA|000035049979‏
996 ‎‡2  LC|no2020123093‏
996 ‎‡2  RERO|A003198084‏
996 ‎‡2  NII|DA07764819‏
996 ‎‡2  CAOONL|ncf10026909‏
996 ‎‡2  N6I|vtls000822276‏
996 ‎‡2  LC|n 93042173‏
996 ‎‡2  ISNI|0000000038952024‏
996 ‎‡2  N6I|vtls000273620‏
996 ‎‡2  LC|n 84079827‏
996 ‎‡2  LC|no2021098475‏
996 ‎‡2  ISNI|0000000024666756‏
996 ‎‡2  J9U|987007420680005171‏
996 ‎‡2  ISNI|0000000421139415‏
996 ‎‡2  NKC|mzk2006320226‏
996 ‎‡2  NTA|073123072‏
996 ‎‡2  BIBSYS|90525725‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏